Analyst Says He Likes AbbVie (ABBV) Amid 'Attractive' Valuation

We recently published 10 Stock News You Should Not Miss as Tom Lee Reiterates Bullish Market Outlook Amid AI Catalysts. AbbVie Inc. (NYSE:ABBV) is one of the stock news you should not miss.

Jim Lebenthal from Cerity Partners said in a recent program on CNBC that he likes AbbVie amid “attractive” valuation and dividend yield.

“If I’m a little nervous, just a little nervous, I’m going to go with something that’s kind of on the safe side. AbbVie Inc (NYSE:ABBV). Now, this has been an aggressive name this year, up about 30%, still has a good dividend yield, attractive valuation. So, regardless of whether I need to be nervous, this is a good pick.”

ABBV shares are up 27% so far this year.

Carillon Eagle Growth & Income Fund stated the following regarding AbbVie Inc. (NYSE:ABBV) in its second quarter 2025 investor letter:

“AbbVie Inc.’s (NYSE:ABBV) shares were a detractor for the portfolio in the second quarter. We attribute the weakness primarily to the underperformance of the broader biopharmaceutical industry, which is under pressure as it navigates policy threats from the Trump administration surrounding both tariffs on the pharmaceutical sector and a proposal to explore most-favored nation prescription drug pricing.”

While we acknowledge the potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.